Janata Dal (United) leader K.C. Tyagi said on Friday that he had a problem with yoga guru Baba Ramdev's contention that he had a drug that guarantees the birth of a male child. He said he would not have had a problem had Ramdev said that he had a drug to produce children of any gender.
Lauding the NDA Government's 'Beti Bachao Beti Padhao' campaign, Tyagi said, "I praise the Prime Minister's efforts, but on the other hand, this medicine by Baba Ramdev is called 'Putrajeevak Beej' and I have a problem with that."
"Had the medicine been called 'santaanjeevak beej' I would have had no problem," he added.
On Thursday, there was uproar in the Rajya Sabha during Zero Hour over the medicine being marketed by Baba Ramdev's company.
The opposition called the medicine 'illegal' and 'unconstitutional'.
The Patanjali Yogapeeth and the Divya Yog Mandir had said in a statement that their medicine had nothing to do with sex determination.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
